The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...
The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While ...
Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...
Currently, only 13 states cover GLP-1 drugs for obesity under Medicaid. But a new proposal announced by the Biden ...
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...
Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback